#IDMastodon #Immunopharmacology Drugs #Adverseeffetcs #remdesivir appeared to have a small mortality benefit in #COVID19 hospitalized patients who were not already being ventilated at baseline. Remdesivir was generally well tolerated in #clinicaltrials
#IDMastodon #immunopharmacology #adverseeffetcs #remdesivir #COVID19 #clinicaltrials
#IDMastodon #Immunopharmacology #Pleuralinfection is usually treated with empirical broad-spectrum antibiotics but limited data exists around their penetrance into the infected pleural space.
Whatβs #Fleuralinfection
https://www.sciencedirect.com/topics/medicine-and-dentistry/pleural-infection#:~:text=Pleural%20infection%20commonly%20presents%20with,the%20diagnosis%20is%20often%20unsuspected.
#IDMastodon #immunopharmacology #pleuralinfection #fleuralinfection
#IDMastodon #Immunopharmacology @bmc_series @crit_care
long-term immunosuppressive therapy excluding chemotherapy was not associated with significantly higher or lower #ICU and 3-month mortality in patients admitted to the ICU for #septicshock.
https://ccforum.biomedcentral.com/articles/10.1186/s13054-023-04626-z?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=CONR_JRNLS_AWA1_GL_SCON_SMEDA_BMC
#IDMastodon #immunopharmacology #ICU #septicshock
#IDMastodon #Immunopharmacology
Azvudine could decrease the time of NANC, viral load, and the median time for improvement in clinical conditions and increase the proportion of improvement in clinical conditions on day 7 in patients with moderate #COVID19. Additionally, Azvudine could reduce body temperature normalization time, fever duration, and hospital LOS. In safety analyses, Azvudine exhibited good safety and tolerance.
#IDMastodon #immunopharmacology #COVID19
#IDMastodon #Immunopharmacology @jama_current Interesting Comment & Response on Treatment Effects of Therapeutic-Dose #Heparin in Patients Hospitalized for #COVID19
πhttps://jamanetwork.com/journals/jama/fullarticle/2807755?guestAccessKey=d09dc019-a910-4ed9-8350-7fb18fdc2075&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=etoc&utm_term=08012023
π https://jamanetwork.com/journals/jama/fullarticle/2802856
#IDMastodon #immunopharmacology #heparin #COVID19
#IDMastodon #Immunopharmacology #Drugdevelopment #Microbiology #Clinicalreview Understanding the role & mechanistic actions of protein kinase inhibitors as an drug target for cancer and #COVID19
π https://link.springer.com/article/10.1007/s00203-023-03559-z
π https://link.springer.com/journal/203/volumes-and-issues/205-7
#IDMastodon #immunopharmacology #DrugDevelopment #microbiology #clinicalreview #COVID19
#IDMastodon #Immunopharmacology #ICU #Immunology #viralimmunology Effect of TΞ±1 on reversing severe #lymphocytopenia in #COVID19 patients
https://twitter.com/castltrastondrs/status/1664255259852562434?s=61&t=Yz-0chnQVfpDSt8bfrGiCw
#IDMastodon #immunopharmacology #ICU #immunology #viralimmunology #lymphocytopenia #COVID19
#Immunopharmacology #IDmastodon @JAMAInternalMed #Paxlovid know your #COVID19 Drugs .Common Drug Interactions With #Nirmatrelvir & #Ritonavir Story From the Front Lines
π https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2801429?guestAccessKey=731b2fd7-b7a4-4bf8-aee3-fdaef1ece064&utm_source=twitter&utm_medium=social_jamaim&utm_term=8966395629&utm_campaign=article_alert&linkId=202308444
π https://jamanetwork.com/journals/jamainternalmedicine/currentissue
#immunopharmacology #IDMastodon #Paxlovid #COVID19 #nirmatrelvir #ritonavir
#IDMastodon #NeuroCovid #Immunopharmacology #ICU Treatment with dexamethasone, remdesivir, or both in patients hospitalized with #COVID19 was associated with a lower frequency of neurological complications in an additive manner, such that the greatest benefit was observed in patients who received both drugs together
https://onlinelibrary.wiley.com/doi/10.1002/ana.26536
#IDMastodon #neurocovid #immunopharmacology #ICU #COVID19
#IDMastodon #Immunopharmacology @NIH provides descriptions of the ACTIV therapeutic adaptive master protocols; information about ACTIV clinical trials that are ongoing, completed, or ended; and information about ACTIV-associated #COVID19 #clinicaltrials involving therapeutic agents prioritized by ACTIV
πhttps://www.nih.gov/research-training/medical-research-initiatives/activ/covid-19-therapeutics-prioritized-testing-clinical-trials
#IDMastodon #immunopharmacology #COVID19 #clinicaltrials
#IDMastodon #Immuonology #DrugDevelopment #Immunopharmacology A #Clinicalreviews about the development, challenges and prospects of #COVID19 vaccines, it can provide more insights into all aspects of the vaccines and The current research status of the #COVID19vaccines
π https://www.sciencedirect.com/science/article/pii/S0753332222015979
#IDMastodon #immuonology #DrugDevelopment #immunopharmacology #Clinicalreviews #COVID19 #COVID19vaccines
#Clinicalreviews 2023 #IDmastodon #Immunopharmacology Evaluation the efficacy and safety of nafamostat combined with favipiravir for #COVID19
πhttps://www.sciencedirect.com/science/article/pii/S1201971222006841?dgcid=raven_sd_aip_email
π https://pubchem.ncbi.nlm.nih.gov/compound/Favipiravir
π https://pubchem.ncbi.nlm.nih.gov/compound/5311180
π https://www.sciencedirect.com/journal/international-journal-of-infectious-diseases
#Clinicalreviews #IDMastodon #immunopharmacology #COVID19
#IDMastodon #Immunology #Immunopharmacology impacts of vaccination status & host factors during early infection on #SarsCoV2 persistence.
π https://www.sciencedirect.com/science/article/pii/S1567576922010190
π https://www.sciencedirect.com/journal/international-immunopharmacology/vol/114/suppl/C
πhttps://www.sciencedirect.com/science/article/pii/S1567576922009134?dgcid=raven_sd_recommender_email#f0010
π https://www.sciencedirect.com/journal/international-immunopharmacology/vol/113/part/PB
#IDMastodon #immunology #immunopharmacology #SarsCoV2